NO20071591L - Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav. - Google Patents

Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.

Info

Publication number
NO20071591L
NO20071591L NO20071591A NO20071591A NO20071591L NO 20071591 L NO20071591 L NO 20071591L NO 20071591 A NO20071591 A NO 20071591A NO 20071591 A NO20071591 A NO 20071591A NO 20071591 L NO20071591 L NO 20071591L
Authority
NO
Norway
Prior art keywords
interleukin
methods
chimeric
mutein
antagonists
Prior art date
Application number
NO20071591A
Other languages
English (en)
Inventor
David C Boisvert
Malinda Longphre
Teresa M Wong
Sydney M Zaremba
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of NO20071591L publication Critical patent/NO20071591L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Kimæriske polypeptidantagonister som innbefatter et interleukin-4- (IL-4)-mutein bundet til et interleukin-9- (IL-9)-mutein er tilveiebrakt, og likeledes polynukleotider som koder for de kimæriske IL-4- og IL-9-muteinantagonister. Det er også tilveiebrakt metoder for anvendelse av de kimæriske muteinantagonister og kodende polypeptider til redusering eller hemming av en celles responsivitet overfor et cytokin så som IL-4, IL-9 og/eller interleukin-13. Metoder for anvendelse av preparatene til behandling av sykdommer så som lungesykdommer (feks. astma) er også tilveiebrakt.
NO20071591A 2004-09-22 2007-03-27 Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav. NO20071591L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61227504P 2004-09-22 2004-09-22
US11/026,396 US7635754B2 (en) 2004-09-22 2004-12-29 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
PCT/US2005/034388 WO2006036878A2 (en) 2004-09-22 2005-09-21 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same

Publications (1)

Publication Number Publication Date
NO20071591L true NO20071591L (no) 2007-06-21

Family

ID=36074534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071591A NO20071591L (no) 2004-09-22 2007-03-27 Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.

Country Status (12)

Country Link
US (2) US7635754B2 (no)
EP (1) EP1805198A4 (no)
JP (1) JP2008513518A (no)
KR (1) KR20070068396A (no)
AU (1) AU2005289639A1 (no)
BR (1) BRPI0516776A (no)
CA (1) CA2581469A1 (no)
IL (1) IL181898A (no)
NO (1) NO20071591L (no)
NZ (1) NZ553897A (no)
RU (1) RU2007114958A (no)
WO (1) WO2006036878A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006244479B2 (en) 2005-05-05 2012-08-09 Nyse Group, Inc. Unpriced order auction and routing
AU2006244483B2 (en) 2005-05-05 2012-05-31 Nyse Group, Inc. Tracking liquidity order
WO2006121687A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Reprice-to-block order
US7912775B1 (en) 2005-05-05 2011-03-22 Archipelago Holdings, Inc. Liquidity analysis system and method
US7873561B1 (en) 2005-05-05 2011-01-18 Archipelago Holdings, Inc. Method and system for maintaining an order on a selected market center with maximum price exemption parameter
MX2008008968A (es) * 2006-01-11 2008-09-10 Aerovance Inc Metodos y composiciones para tratar asma en primates humanos y no humanos.
EP2178547A4 (en) * 2007-07-11 2011-02-16 Aerovance Inc PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
JP2019518724A (ja) * 2016-04-26 2019-07-04 ファイブ プライム セラピューティックス インコーポレイテッド インターロイキン４誘導１（ｉｌ４ｉ１）の標的化による呼吸器疾患の治療
WO2018182935A1 (en) * 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Synthekine compositions and methods of use
ES2971898T3 (es) * 2018-02-27 2024-06-10 Univ Der Johannes Gutenberg Univ Mainz Nuevos compuestos peptídicos obtenidos a partir de IL-4-/IL-13 para el tratamiento o la prevención de enfermeda-des neurodegenerativas o neuroinflamatorias
WO2022032045A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL10Rα/IL2Rγ SYNTHETIC CYTOKINES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5314695A (en) 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
JPH10503371A (ja) * 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
CA2230240C (en) * 1995-08-24 2009-08-18 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
EP0918858A1 (en) * 1996-05-10 1999-06-02 Biogen, Inc. Common gamma chain blocking agents
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
ATE473239T1 (de) 2003-05-14 2010-07-15 Bayer Pharmaceuticals Corp Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren

Also Published As

Publication number Publication date
AU2005289639A1 (en) 2006-04-06
NZ553897A (en) 2011-01-28
IL181898A0 (en) 2007-07-04
IL181898A (en) 2011-04-28
JP2008513518A (ja) 2008-05-01
BRPI0516776A (pt) 2008-09-23
WO2006036878A2 (en) 2006-04-06
CA2581469A1 (en) 2006-04-06
RU2007114958A (ru) 2008-10-27
KR20070068396A (ko) 2007-06-29
EP1805198A2 (en) 2007-07-11
US7635754B2 (en) 2009-12-22
US20100099618A1 (en) 2010-04-22
WO2006036878A3 (en) 2009-04-09
EP1805198A4 (en) 2010-01-20
US20060063236A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
NO20071591L (no) Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.
WO2002020767A3 (en) G-csf analog compositions and methods
WO2004058717A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
NZ603562A (en) Tear lipocalin muteins binding il-4 r alpha
EA201070129A1 (ru) Фармацевтический сухой порошкообразный аэрозольный состав, включающий полипептид, и способ его приготовления
BRPI0212919B8 (pt) "muteínas da lipocalina associada à gelatinase de neutrófilos humanos, proteínas relacionadas, composição farmacêutica, método para geração e uso das mesmas".
EP1997512A3 (en) Methods for treating TWEAK-related conditions
EP2042196A3 (en) Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
AU2003257980A1 (en) Respiratory analyzer for exercise use
NO20052894L (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DK1722043T3 (da) Træbeklædning til uden- og indendørs brug
DK471386D0 (da) Farmaceutisk komposition til behandling af leukopeni
NO20063375L (no) Agonist-anti-trkC-antistoffer og fremgangsmater for a anvende disse
EP0907719A4 (en) HUMAN CYTOKINE POLYPEPTIDE
DE60107416D1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
NO20081081L (no) Nytt salt II
NO971378L (no) Cytokin betegnet LERK-6
WO2003010290A3 (en) Novel class ii cytokine receptors and uses thereof
DK1808179T3 (da) Anvendelse af HSP20 til fremme af sårheling og/eller til formindskelse af ardannelse
DK1660532T3 (da) Fusionspolypeptider, og anvendelse deraf i antivaskulær tumorterapi
ES2531085T3 (es) Fracciones de permeado de suero de leche y su uso para la prevención y la terapia de diabetes de tipo 2 y de síndrome metabólico
TW200630357A (en) N-heterocyclylphthaldiamides
DK1022337T3 (da) Plasmider, deres konstruktion og deres anvendelse til fremstilling af interleukin-4 og interleukin-4-muteiner
NO20081080L (no) Nytt salt I

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application